GTCbio, Washington DC
September 18-19, 2006
Day 1 - Monday, September 18, 2006
Session 1 - Alzheimer's Disease
8:00 Gamma-Secretase Inhibitors as Tools to Investigate the Processing of Beta-Amyloid In Vivo
Donna Barten, Bristol-Myers Squibb 8:30 Building a World Leading Pipeline of Disease-Modifying Treatments for Alzheimer's Disease
Steven Jacobsen, Ph.D., Associate Director, Neuroscience,
Wyeth Research 9:00 The Design and Development of Biologically Active BACE1 Inhibitors for the Treatment of Alzheimer’s Disease
Ginnie Yang, Eli Lilly
9:30 Refreshment Break
9:45 Keynote Presentation: Jackie Hunter
10:30 Identification of Candidate Late-Onset Alzheimer’s Disease Susceptibility Genes by a Genome-Wide siRNA Screen
Kenneth S. Koblan, Ph.D., Vice President , WPHH, Neuroscience Drug Discovery, Merck Research Laboratories
11:00 TBA
Peter Reinhart, Senior Director, Neurodegeneration, Discovery Neuroscience, Wyeth Research
11:30 APOE4 and Alzheimer's Disease: From Susceptibility Gene Variant to Clinical Trial to New Drug Discovery
Ann Saunders, Ph.D., Therapy Area Team Leader, Metabolic & Viral Diseases, GlaxoSmithKline 12:00 TBA
Grant Krafft, Chairman and Chief Science Officer,
Acumen Pharmaceuticals, Inc. 12:30 Lunch
Session 2 - Parkinson's Disease
1:30 Inducible Mouse Models of Parkinson's-related Events: What These Can Teach Us About Possible Therapeutics
Julie Andersen, Ph.D., Professor, Buck Institute for Age Research 2:00 Parkinson's Disease: Mechanisms and Models
Serge Przedborksi, M.D., Ph.D., William Black Professor of Neurology, Center for Neurobiology and Behavior, Departments of Neurology and Pathology,
Columbia University Medical Center
2:30 Parkinson's disease: TBD
Marcelle Bergeron, Principal Scientist, Department of Neuroscience, Amgen 3:00 Novel Targets for Parkinson's Disease
Kalpana Merchant, Eli Lilly
3:30 Refreshment Break 4:00 Disease Modifying Targets for Parkinsons' Disease: Genetic, Pharmacological and Neurotrophic Approaches
Michael O’Neal, Principal Research Scientist/Team and Project Leader, Neurodegeneration Group, Eli Lilly
4:30 Gene Delivery of NTN for Treating PD Patients
Raymond T. Bartus, Ph.D. Senior V.P., Clinical and Preclinical R&D, Chief Operating Officer, Ceregene, Inc.
5:00 Ubiquitin-proteasome Pathway and Neurodegeneration
Jennifer A. Johnston, Principal Scientist, Elan Pharmaceuticals
5:30 Networking Reception/ Poster Session
Day 2 - Tuesday, September 19, 2006
Therapeutic Strategies against Neurodegenerative Conditions
(Continued from Previous Day) Partnering, Licensing & Alliance Management for Neuro-focused Organizations Summit
Session 3 - Programmed Cell Death & Neurodegeneration Check-In Begins for Individual Partnering Sessions
Meeting space will be available for 25 minute private meetings throughout the Summit.
7:30 The Cell Cycle: An Unusual but Promising Therapeutic Target for Alzheimer's Disease
Inez Vincent, Department of Pediatrics,
Centre for Molecular Medicine and Therapeutics, University of British Columbia 8:00 The Regulation of Neuronal Death: Defining the Pathways
Carol Troy, M.D., Ph.D., Associate Professor of Clinical Pathology and Neurology, Taub Center for the Study of Alzheimer's Disease and the Aging Brain,
Columbia University College of Physicians and Surgeons Current Alliances and Market Trends 8:30 Molecular Pathways to Neurodegeneration
Ella Bossy-Wetzel, Ph.D., Program for Apoptosis and Cell Death, The Burnham Institute Panel Discussion:
Private Equity Funding for the Biotech Industry How Private Companies are being funding today and how can you take advantage of these opportunities. 9:00 Beyond Programmed Cell Death: Alternative Pathways of Neurodegeneration
Kevin Roth, M.D., Ph.D., Professor of Pathology,
Director of Neuropathology, University of Alabama at Birmingham 9:30 Refreshment Break 9:45 Keynote Presentation:
Cell Death and Survival in Neurodegenerative Diseases
Ted Dawson, Johns Hopkins University School of Medicine
Session 4 - Novel Drug Targets & Neuroprotective Compounds FOCUS ON PARTNERING 10:30 Prolyl hydroxylases as therapuetic targets for neurodegeneration
Robert Freeman, Associate Professor, Dept. of Pharmacology and Physiology, University of Rochester School of Medicine The Role of Big Pharma in the Advancement of Biotech 11:00 TBA
Santosh D’Mello, Professor, Department of Molecular & Cell Biology, University of Texas at Dallas Tapping into the Asian Market 11:30 Valproate-induced Gene Expression and Neuroprotection: Role of HDAC Inhibition
De-Maw Chuang, Ph.D., Chief, Section on Molecular Neurobiology, NIMH, National Institutes of Health Panel Discussion:
Co-Development Partnerships What exactly is "co-development" and how can it benefit you? Experts from Big Pharma, Specialty Pharma and Big Biotech will discuss their experiences and insights about developing successful partnerships 12:00 A Mitochondrial Mechanism of Neuroprotective Action of Estrogens and their Non-feminizing Analogues
James Simpkins, Ph.D., Professor & Chair,
Department of Pharmacology & Neuroscience, University of North Texas Health Science Center 12:30 Cyclin Dependent Kinases; Targets for Neuronal Death
David Park, Associate Professor, Neuroscience East
Ottawa Health Research Institute The Perils of Partnering
1:00 Lunch
Session 5 - Other Neurodegenerative Diseases and Therapies FOCUS ON LICENSING
2:00 Building a Pipeline of Novel Therapeutics for Neurodegenerative Diseases Using Phenotypic Screening
Gerhard Koenig, En Vivo Pharmaceuticals Maximizing Value from your Licensing Agreements 2:30 Targeting Inflammation in MS
Jacqueline Kirschner, Amgen Out-licensed Products and Spin-Outs 3:00 New Strategies for Drug Target Discovery in Neurodegenerative Disorders
Floyd Bloom, Founding CEO , and Chairman, Neurome Inc. Negotiating Deal Terms 3:30 Refreshment Break 3:45 Therapeutic utility of NAALADase inhibitors in neurodegenerative diseases, Takashi Tsukamoto, MGI Pharma Expert Debate:
IP and Open Source Initiatives in Drug Development A Pro vs. Con debate. What are the potential benefits of giving away your "trade secrets"? Could this really work for Pharma and Biotech? 4:15 TBA
Jack Barber, CytRx Panel Discussion:
Alliance Management How to reduce risks and maximize your results. Hear case studies and real-life experience on how to create and maintain successful alliances.
4:45 Translational Bioimaging Strategies for Neurodegenerative Disease
Diane Stephenson, Pfizer Inc. 5:15 The Neuroprotective Activity of the PDE4 Inhibitor MEM 1414
David Lowe, Memory Pharmaceuticals Informal Networking
5:45 Conference Concludes
|